Kite Pharma, Inc. 4
4 · Kite Pharma, Inc. · Filed Mar 2, 2017
Insider Transaction Report
Form 4
DOUMANI ROY
Director
Transactions
- Sale
Common Stock
2017-03-01$72.27/sh−10,000$722,673→ 121,017 total - Exercise/Conversion
Common Stock
2017-03-01$1.35/sh+50,000$67,500→ 75,065 total - Sale
Common Stock
2017-03-01$76.77/sh−2,800$214,942→ 25,065 total(indirect: By Spouse) - Exercise/Conversion
Employee Stock Option (Right to Buy)
2017-03-01−50,000→ 75,065 totalExercise: $1.35Exp: 2024-03-24→ Common Stock (50,000 underlying) - Sale
Common Stock
2017-03-01$77.03/sh−6,000$462,200→ 115,017 total
Footnotes (1)
- [F1]1/36th of the shares subject to the stock option vested immediately, and the remaining shares vested in 35 equal monthly installments commencing March 31, 2014.